1. Home
  2. BBY vs RPRX Comparison

BBY vs RPRX Comparison

Compare BBY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBY
  • RPRX
  • Stock Information
  • Founded
  • BBY 1966
  • RPRX 1996
  • Country
  • BBY United States
  • RPRX United States
  • Employees
  • BBY N/A
  • RPRX N/A
  • Industry
  • BBY Consumer Electronics/Video Chains
  • RPRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBY Consumer Discretionary
  • RPRX Health Care
  • Exchange
  • BBY Nasdaq
  • RPRX Nasdaq
  • Market Cap
  • BBY 16.0B
  • RPRX 14.2B
  • IPO Year
  • BBY N/A
  • RPRX 2020
  • Fundamental
  • Price
  • BBY $68.92
  • RPRX $33.21
  • Analyst Decision
  • BBY Buy
  • RPRX Strong Buy
  • Analyst Count
  • BBY 19
  • RPRX 4
  • Target Price
  • BBY $90.89
  • RPRX $42.50
  • AVG Volume (30 Days)
  • BBY 3.9M
  • RPRX 3.9M
  • Earning Date
  • BBY 05-29-2025
  • RPRX 05-08-2025
  • Dividend Yield
  • BBY 5.47%
  • RPRX 2.66%
  • EPS Growth
  • BBY N/A
  • RPRX 37.42
  • EPS
  • BBY 4.28
  • RPRX 2.45
  • Revenue
  • BBY $41,528,000,000.00
  • RPRX $2,263,576,000.00
  • Revenue This Year
  • BBY $0.76
  • RPRX $31.30
  • Revenue Next Year
  • BBY $1.89
  • RPRX $5.82
  • P/E Ratio
  • BBY $16.22
  • RPRX $13.52
  • Revenue Growth
  • BBY N/A
  • RPRX 1.12
  • 52 Week Low
  • BBY $54.99
  • RPRX $24.05
  • 52 Week High
  • BBY $103.71
  • RPRX $34.20
  • Technical
  • Relative Strength Index (RSI)
  • BBY 54.84
  • RPRX 60.48
  • Support Level
  • BBY $66.07
  • RPRX $31.97
  • Resistance Level
  • BBY $70.40
  • RPRX $34.11
  • Average True Range (ATR)
  • BBY 2.03
  • RPRX 0.70
  • MACD
  • BBY 0.93
  • RPRX 0.11
  • Stochastic Oscillator
  • BBY 83.94
  • RPRX 77.47

About BBY Best Buy Co. Inc.

With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: